Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.79 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.79 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625968 | 1.00 | PTGER4 (1.00) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL11885702 | 1.00 | PTGER4 (1.00) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL29516796 | 1.00 | PTGER4 (1.00) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL4998631 | 0.99 | PTGER4 (0.98) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL11885706 | 0.94 | PTGER4 (0.88) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL4984492 | 0.93 | PTGER4 (0.86) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL4984495 | 0.93 | PTGER4 (0.86) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL4998635 | 0.92 | PTGER4 (0.86) | PTGER4PTGER3PTGER1PTGER2 | |
| SCHEMBL7116143 | 0.90 | PTGER1 (0.82) | PTGER4PTGER3PTGER1 | |
| SCHEMBL4984464 | 0.90 | PTGER1 (0.82) | PTGER4PTGER3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414071-B2 | Methods of treatment with selective EP4 receptor agonists | PFIZER INC. (US) | 2008-08-19 | — | — | US | claimed |
| EP-1339678-B1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PROD INC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070191319-A1 | Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen | PFIZER INC. (US) | 2007-08-16 | — | — | US | claimed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | claimed |
| EP-1696893-A1 | CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4, RECEPTOR AGONISTS AND AN ESTROGEN FOR THE TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS. | Pfizer Products Incorporated (US) | 2006-09-06 | — | — | EP | claimed |
| EP-1487437-B1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES | PFIZER PROD INC (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2005060946-A1 | CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4, RECEPTOR AGONISTS AND AN ESTROGEN FOR THE TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | claimed |
| EP-1487437-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2004-12-22 | — | — | EP | claimed |
| US-6747054-B2 | FOR THERAPY OF LOW BONE MASS, PARTICULARLY OSTEOPOROSIS, FRAILTY, AN OSTEOPOROTIC FRACTURE, A BONE DEFECT, CHILDHOOD IDIOPATHIC BONE LOSS, ALVEOLAR BONE LOSS, MANDIBULAR BONE LOSS, BONE FRACTURE, OSTEOTOMY | PFIZER INC. | 2004-06-08 | — | — | US | claimed |
| US-20030207925-A1 | Methods of treatment with selective EP4 receptor agonists | CAMERON KIMBERLY O (US) | 2003-11-06 | — | — | US | claimed |
| WO-2003077910-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-09-25 | — | — | WO | claimed |
| EP-1339678-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | claimed |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O (US) | 2003-08-07 | — | — | US | claimed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | claimed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | claimed |
| CN-112481211-B | Cells with increased immunomodulation and methods of use and production thereof | 儿童医院公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-2499242-B1 | METHODS TO ENHANCE DELIVERY AND ENGRAFTMENT OF STEM CELLS INCLUDING THE IDENTIFICATION OF SPECIFIC PROSTAGANDIN E2 RECEPTORS | UNIV INDIANA RES & TECH CORP (US) | 2019-05-01 | — | — | EP | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191319-A1 | Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen | PTGER4, PTGER1, PTGFR | PTGER4 1/4885PTGER3 4/4885PTGER1 2/4885 |
| US-20030207925-A1 | Methods of treatment with selective EP4 receptor agonists | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER1 2/4885 |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER1 2/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.